Pharmaceuticals & Therapeutics

The FDA's approval of a potent new triglyceride drug comes with a staggering price tag, forcing a showdown with an established, affordable therapy.

Millions suffer from chronic cough with no cure. A Boston biotech is testing a novel aerosol that targets the root cause, not just symptoms. Could it be the first disease-modifying treatment?

Kowa's pemafibrate gets FDA Breakthrough status for a rare liver disease. We dissect what this means for patients, the science, and the company's global strategy.

Artelo Biosciences uses advanced analytics to link its lead drug to a core disease pathway, a strategic move to de-risk development and attract major partners.

NurExone's modest C$628k funding isn't a sign of weakness, but a masterclass in biotech survival. It's a strategic play in a cautious market.

With a new U.S. patent, Quoin Pharmaceuticals reinforces its strategy for QRX003, a potential first-ever treatment for devastating Netherton Syndrome.

Sarepta seeks full FDA approval for two Duchenne drugs, leaning on real-world evidence after a key trial missed its goal. A test case for rare disease innovation.

New Phase 1 data suggests vamorolone delivers potent anti-inflammatory effects without the severe immunosuppression of traditional steroids at clinical doses.

Following a $103M funding round, Kinaset Therapeutics adds proven dealmakers to its board, signaling a strategic push for its novel inhaled asthma therapy.

Vistagen's Phase 3 trial for its novel anxiety nasal spray fails its main goal, but a surprising signal in severe cases prompts a high-stakes pivot.

Will Therapeutics lands $3.5M to develop the first targeted drug for anorexia, aiming to treat the biological roots of compulsion. A breakthrough in the making?

Biotech firm R1 Therapeutics forms a star-studded advisory board to guide its promising kidney disease drug, AP306, into crucial Phase 2b trials.

Skyhawk Therapeutics' oral drug SKY-0515 not only stabilized but appeared to improve key metrics in Huntington's patients, a profound shift in a field long awaiting a breakthrough.

Promising 12-month trial data for SKY-0515 shows it may halt Huntington's, a first for an oral pill. This could disrupt the neuro-market.

Cytonics completes a key safety trial for its novel osteoarthritis drug, CYT-108. But the real story is a masterclass in strategic innovation.

With FDA clearance, Gain Therapeutics' GT-02287, an AI-discovered drug, advances to Phase 2, offering a new hope to modify Parkinson's, not just its symptoms.

A wave of precision drugs for Nephrotic Syndrome is set to transform patient lives and a quiet $400M market, revealing a major shift in pharma strategy.

Artelo Biosciences advances a novel non-opioid painkiller, using AI to map its effects and potentially revolutionize how we treat chronic pain.

A new patent for a non-hallucinogenic compound positions Clearmind Medicine to disrupt the multi-billion dollar market for addiction and compulsive disorders.